• First Subject Dosed in Olorinab Trial for Abdominal Pain from IBS americanpharmaceuticalreview
    July 26, 2019
    rena Pharmaceuticals announced the first subject has been dosed in the Phase 2 CAPTIVATE trial evaluating olorinab, an investigational, oral, highly-selective, full agonist of the cannabinoid type 2 receptor (CB2) in development for ...
PharmaSources Customer Service